Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to -$1.1 million.

  • Caribou Biosciences' Change in Accured Expenses fell 17040.56% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.7 million, marking a year-over-year decrease of 17920.12%. This contributed to the annual value of $2.1 million for FY2024, which is 6284.17% down from last year.
  • Per Caribou Biosciences' latest filing, its Change in Accured Expenses stood at -$1.1 million for Q3 2025, which was down 17040.56% from $688000.0 recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Change in Accured Expenses ranged from a high of $5.0 million in Q2 2024 and a low of -$4.1 million during Q1 2023
  • Moreover, its 5-year median value for Change in Accured Expenses was $688000.0 (2025), whereas its average is $557210.5.
  • Per our database at Business Quant, Caribou Biosciences' Change in Accured Expenses soared by 167644.23% in 2023 and then tumbled by 17623.49% in 2024.
  • Quarter analysis of 5 years shows Caribou Biosciences' Change in Accured Expenses stood at -$574000.0 in 2021, then soared by 281.88% to $1.0 million in 2022, then surged by 177.3% to $2.9 million in 2023, then crashed by 176.23% to -$2.2 million in 2024, then surged by 49.66% to -$1.1 million in 2025.
  • Its Change in Accured Expenses stands at -$1.1 million for Q3 2025, versus $688000.0 for Q2 2025 and -$3.1 million for Q1 2025.